In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is ...

Diffuse cutaneous systemic sclerosis (“dcSSc”) is a rare, progressive autoimmune disease characterized by immune activation, vasculopathy and fibrosis affecting the skin and internal organs, including ...

When Elise Felicione tried to design a clinical trial for a supplement, 5 things got in the way. It’s a lesson for the ...

Adaptive clinical trial design represents a modern approach to evaluating healthcare interventions that allows pre‐specified modifications based on accumulating data. This flexible methodology ...

As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...

Simulations of a real-world explanatory trial of transarterial radioembolization for advanced unresectable hepatocellular carcinoma with portal vein invasion were performed to examine the effects of ...

Clinical trials can vary in length depending on several factors. Here's what you need to know about how long clinical trials last.

This international Delphi study, led by the European Society of Radiation Oncology as part of their Value-Based Radiation Oncology programme, brought together key experts from the radiation oncology ...

A common thread in your work has been connecting people to clinical trials. Was that the focus in founding the CARE Research Center? The impetus behind the CARE Research Center is probably not so ...

Momentum in biotech IPOs continued this week as four more companies made their stock market debuts. IPO activity is higher this year by several measures, according to IPO research firm Renaissance ...